OR WAIT null SECS
February 14, 2019
The companies will use a $4.4-million grant from the National Institute of Allergy and Infectious Diseases to discover sustainable alternatives to shark squalene to use as vaccine adjuvants.
February 11, 2019
C-Bridge Capital will form a new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-generation biosimilars in China.
The strategic partnership is expected to bring a new source of supply to providers, alleviating in particular the two-year shortage of metoprolol injection.
February 08, 2019
The companies will jointly develop and commercialize an investigational bifunctional fusion protein immunotherapy currently in clinical development for cancer treatment.
February 06, 2019
The companies will develop Amprologix’s lead epidermicin-based antibiotic candidate.
In a deal potentially worth up to $460 million, Genentech and Xencor will develop and commercialize novel cytokine therapeutics.
February 04, 2019
Company launches new services dedicated to emerging biotech and biopharma companies.
February 02, 2019
Biosimilars, pricing strategies, and technology will influence growth in spending on drugs.
February 01, 2019
A Memorandum of Understanding (MoU) has been signed by the UK’s MHRA and the State Institute of Drugs and Good Practices of the Ministry of Industry and Trade of the Russian Federation.
TrakCel and WindMIL Therapeutics have formed a partnership to build a custom-configured cellular supply chain tracking and orchestration platform.